CILTA- CEL Or Standard Care in Lenalidomide-Refractory Multiple Myeloma .
List of authors :
Jesús San-Miguel, M.D., Ph.D.,
Binod Dhakal, M.D.,
Kwee Yong, Ph.D.,
Andrew Spencer, M.D. .
CONCLUSIONS :
A Single CILTA - Cel Infusion Resulted in a Lower Risk Of Disease Progression Or Death Than Standard Care in Lenalidomide - Refractory Patients With Múltiple Myeloma Who Had Received One To Three Previous Therapies. (Funded by Janssen and Legend Biotech ;
CARTITUDE-4 ClinicalTrials.gov Number, NCT04181827. Opens in New tab.) .